Summary

CYP2C9 and VKORC1 together determine warfarin sensitivity — combined genotyping is the gold standard for predicting safe warfarin dose, and CYP2C9 status also affects NSAID metabolism and GI bleeding risk.

Genotype spectrum

CC

Standard drug clearance. No dose adjustments needed for CYP2C9 substrates.

CT

You're more sensitive to CYP2C9 drugs — lower doses may work better with fewer side effects.

TT

Drug sensitivity means lower doses achieve full effect.

AA

Standard CYP2C9 function.

AC

The *3 allele has a larger functional impact than *2 — your sensitivity is well-characterised and highly actionable.

CC

Extremely well-studied — dosing algorithms are precise for your genotype.

GG

Standard warfarin target sensitivity. You may need higher warfarin doses, which is straightforward to manage.

GA

Lower warfarin doses achieve target INR — less drug exposure overall.

AA

Significantly lower warfarin doses needed — minimal drug exposure for full effect.

Practical takeaway

For warfarin users (or potential future users):
• Record your CYP2C9 and VKORC1 genotype in your medical records and share with any prescriber initiating warfarin.
• FDA-approved dosing algorithms (warfarindosing.org) use both genotypes plus clinical factors to calculate starting dose.
• Genotype-guided initiation reduces over-anticoagulation events in the critical first 1-4 weeks.
• Dietary vitamin K consistency matters more for VKORC1 A allele carriers — sudden changes in green vegetable intake cause larger INR swings.

For NSAID users (CYP2C9 relevant):
• If CYP2C9 intermediate or poor: prefer paracetamol for routine pain. Use NSAIDs at the lowest effective dose for the shortest duration.
• CYP2C9 poor metabolisers should avoid prolonged NSAID courses without monitoring.
• Topical NSAIDs (diclofenac gel) bypass hepatic metabolism — a practical alternative for musculoskeletal pain.
• Celecoxib is a CYP2C9 substrate — FDA labelling already recommends half the starting dose for CYP2C9 poor metabolisers.

Tracking:
• INR monitoring during warfarin therapy (standard clinical practice, not self-managed).
• GI symptom awareness with NSAID use if CYP2C9 intermediate/poor.

Evidence detail

What This Gene Does

CYP2C9 is a cytochrome P450 enzyme responsible for metabolising approximately 15% of clinically used drugs, including warfarin (specifically the more potent S-enantiomer) and most NSAIDs (ibuprofen, diclofenac, celecoxib). The 2 and 3 alleles reduce enzyme activity, meaning drugs are cleared more slowly and reach higher blood levels at standard doses.

VKORC1 encodes vitamin K epoxide reductase — the enzyme warfarin is designed to inhibit. The -1639G>A promoter variant (rs9923231) reduces VKORC1 expression, meaning less enzyme is produced. Less target enzyme means less warfarin is needed to achieve anticoagulation. These two genes are combined in one entry because warfarin dosing requires both: CYP2C9 determines how fast you clear warfarin, VKORC1 determines how sensitive your target is.

Mechanism

CYP2C9 pathway: Warfarin exists as R- and S-enantiomers. S-warfarin is 3-5 times more potent and is primarily metabolised by CYP2C9 to inactive 7-hydroxywarfarin. The 2 allele (Arg144Cys) disrupts a surface loop affecting substrate binding — reducing metabolic capacity to ~50% of wild-type. The 3 allele (Ile359Leu) is in the active site — reducing capacity to ~10% of wild-type. Reduced CYP2C9 activity means S-warfarin accumulates, producing greater anticoagulant effect per dose.

VKORC1 pathway: Warfarin inhibits VKORC1, which recycles vitamin K epoxide back to reduced vitamin K — essential for activating clotting factors II, VII, IX, and X. The rs9923231 A allele reduces VKORC1 promoter activity, producing less enzyme. Less target means less warfarin required for the same degree of clotting factor suppression.

Combined effect: CYP2C9 variants increase warfarin exposure (pharmacokinetic). VKORC1 variants increase warfarin sensitivity (pharmacodynamic). Together they explain ~40-50% of dose variability. The remaining variance comes from clinical factors (age, body weight, interacting medications, diet).

CYP2C9 and NSAIDs: The same enzyme metabolises ibuprofen, diclofenac, celecoxib, and other NSAIDs. Poor metabolisers have higher drug exposure at standard doses, increasing risk of GI bleeding, renal effects, and cardiovascular events with prolonged use.

CYP2C9 + VKORC1 Vkorc1

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (8)